INIS
patients
100%
biological markers
50%
organoids
50%
budgets
50%
colon
50%
lymphomas
50%
tumors
30%
plasma
22%
levels
18%
stem cells
16%
tissues
16%
organs
11%
drugs
11%
cancer
10%
origin
5%
ultracentrifugation
5%
microscopy
5%
biopsy
5%
surgery
5%
therapy
5%
cost
5%
tools
5%
offsprings
5%
laboratories
5%
cell cultures
5%
resolution
5%
range
5%
adults
5%
comparative evaluations
5%
Medicine and Dentistry
Biological Marker
50%
Disseminated Intravascular Coagulation
50%
Thrombosis
50%
Procoagulant
50%
Acute Leukemia
50%
Organoid
50%
Biochemical Analysis
50%
Colon
50%
Neoplasm
16%
Thromboplastin
11%
Thrombin
11%
Venous Thromboembolism
5%
Health Care Cost
5%
Hemostat
5%
Bleeding
5%
Translational Research
5%
Hematologic Malignancy
5%
Colorectal Cancer
5%
Pluripotent Stem Cell
5%
Child
5%
Embryonic Stem Cell
5%
Personalized Medicine
5%
Immunoassay
5%
Drug Therapy
5%
Drug Response
5%
Biopsy
5%
Adult Stem Cell
5%
Surgery
5%
Immunoblotting
5%
Cell Culture
5%
Keyphrases
Patient-derived
50%
Budget-friendly
50%
Colonoids
50%
Patient-derived Organoids
25%
Phenotypic Heterogeneity
12%
Two-dimensional Cell Culture
12%
Targeted Drug Therapy
12%
Personalized Therapy
12%
Primary Tissue
12%
Organoid Models
12%
Super-resolution Microscopy
12%
Tissue Factor Expression
10%
Patient with Tumor
6%
MiR-197
6%
Cancer History
6%
Tumor Evolution
6%
MicroRNA-21 (miR-21)
6%
Personalized Treatment
6%
Prognosis Evaluation
6%
MiR-451
6%
Hematological Malignancies
5%
Hemostatic Complications
5%
EV Impacts
5%
Ultracentrifugation
5%
